BACKGROUND: Kidney transplantation is the gold standard renal replacement therapy. Nocturnal haemodialysis (NHD) is an intensive dialysis modality (6-8 h/session, 3-7 sessions/week) associated with a significant improvement of clinical and biochemical parameters compared to conventional dialysis. To date, no studies have compared survival in patients treated with NHD and kidney transplantation. METHODS: Using data from two regional NHD programmes and the USRDS from 1994 to 2006, we performed a matched cohort study comparing survival between NHD and deceased and living donor kidney transplantation (DTX and LTX) by randomly matching NHD patients to transplant recipients in a 1:3:3 ratio. The independent association of treatment modality with survival was determined using Cox multivariate regression. RESULTS: The total study population consisted of 177 NHD patients matched to 1062 DTX and LTX recipients (total 1239 patients) followed for a maximum of 12.4 years. During the follow-up period, the proportion of deaths among NHD, DTX and LTX patients was 14.7%, 14.3% and 8.5%, respectively (P = 0.006). We found no difference in the adjusted survival between NHD and DTX (HR 0.87, 95% CI 0.50-1.51; NHD reference group), while LTX survival was better (HR 0.51, 95% CI 0.28-0.91). CONCLUSIONS: These results indicate that NHD and DTX survival is comparable, and suggest that this intensive dialysis modality may be a bridge to transplantation or even a suitable alternative in the absence of LTX in the current era of growing transplant waiting lists and organ shortage.
BACKGROUND: Kidney transplantation is the gold standard renal replacement therapy. Nocturnal haemodialysis (NHD) is an intensive dialysis modality (6-8 h/session, 3-7 sessions/week) associated with a significant improvement of clinical and biochemical parameters compared to conventional dialysis. To date, no studies have compared survival in patients treated with NHD and kidney transplantation. METHODS: Using data from two regional NHD programmes and the USRDS from 1994 to 2006, we performed a matched cohort study comparing survival between NHD and deceased and living donor kidney transplantation (DTX and LTX) by randomly matching NHDpatients to transplant recipients in a 1:3:3 ratio. The independent association of treatment modality with survival was determined using Cox multivariate regression. RESULTS: The total study population consisted of 177 NHDpatients matched to 1062 DTX and LTX recipients (total 1239 patients) followed for a maximum of 12.4 years. During the follow-up period, the proportion of deaths among NHD, DTX and LTXpatients was 14.7%, 14.3% and 8.5%, respectively (P = 0.006). We found no difference in the adjusted survival between NHD and DTX (HR 0.87, 95% CI 0.50-1.51; NHD reference group), while LTX survival was better (HR 0.51, 95% CI 0.28-0.91). CONCLUSIONS: These results indicate that NHD and DTX survival is comparable, and suggest that this intensive dialysis modality may be a bridge to transplantation or even a suitable alternative in the absence of LTX in the current era of growing transplant waiting lists and organ shortage.
Authors: Nikhil Shah; Frances Reintjes; Mark Courtney; Scott W Klarenbach; Feng Ye; Kara Schick-Makaroff; Kailash Jindal; Robert P Pauly Journal: Clin J Am Soc Nephrol Date: 2017-07-24 Impact factor: 8.237
Authors: Jeffrey Perl; Laura M Dember; Joanne M Bargman; Teri Browne; David M Charytan; Jennifer E Flythe; LaTonya J Hickson; Adriana M Hung; Michel Jadoul; Timmy Chang Lee; Klemens B Meyer; Hamid Moradi; Tariq Shafi; Isaac Teitelbaum; Leslie P Wong; Christopher T Chan Journal: Clin J Am Soc Nephrol Date: 2017-03-17 Impact factor: 8.237
Authors: Robert P Pauly; Katerina Maximova; Jennifer Coppens; Reem A Asad; Andreas Pierratos; Paul Komenda; Michael Copland; Gihad E Nesrallah; Adeera Levin; Anne Chery; Christopher T Chan Journal: Clin J Am Soc Nephrol Date: 2010-07-29 Impact factor: 8.237
Authors: Gihad E Nesrallah; Robert M Lindsay; Meaghan S Cuerden; Amit X Garg; Friedrich Port; Peter C Austin; Louise M Moist; Andreas Pierratos; Christopher T Chan; Deborah Zimmerman; Robert S Lockridge; Cécile Couchoud; Charles Chazot; Norma Ofsthun; Adeera Levin; Michael Copland; Mark Courtney; Andrew Steele; Philip A McFarlane; Denis F Geary; Robert P Pauly; Paul Komenda; Rita S Suri Journal: J Am Soc Nephrol Date: 2012-02-23 Impact factor: 10.121
Authors: Mary Pipkin; Paul W Eggers; Brett Larive; Michael V Rocco; John B Stokes; Rita S Suri; Robert S Lockridge Journal: Clin J Am Soc Nephrol Date: 2010-06-24 Impact factor: 8.237
Authors: Bessie A Young; Christopher Chan; Christopher Blagg; Robert Lockridge; Thomas Golper; Fred Finkelstein; Rachel Shaffer; Rajnish Mehrotra Journal: Clin J Am Soc Nephrol Date: 2012-10-04 Impact factor: 8.237
Authors: Scott Klarenbach; Marcello Tonelli; Robert Pauly; Michael Walsh; Bruce Culleton; Helen So; Brenda Hemmelgarn; Braden Manns Journal: J Am Soc Nephrol Date: 2013-11-14 Impact factor: 10.121